Xin Lang Cai Jing·2025-09-25 01:44Core Viewpoint - Junshi Bioscience's stock price has shown significant volatility, with a year-to-date increase of 55.80% but a recent decline over the past five days of 6.89% [2] Company Overview - Junshi Bioscience, established on December 27, 2012, and listed on July 15, 2020, is located in Shanghai and focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The company's main revenue sources are drug sales (90.67%), technology licensing and royalties (8.74%), and technical services and others (0.59%) [2] Financial Performance - For the first half of 2025, Junshi Bioscience reported revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, an increase of 36.01% year-on-year [2] Stock Performance - As of September 25, Junshi Bioscience's stock price was 42.58 yuan per share, with a market capitalization of 43.716 billion yuan [1] - The stock has experienced a trading volume of 56.48 million yuan and a turnover rate of 0.17% [1] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders include Huaxia SSE Sci-Tech Innovation Board 50 ETF, holding 29.7167 million shares (a decrease of 536,700 shares), and E Fund SSE Sci-Tech Innovation Board 50 ETF, holding 22.2132 million shares (an increase of 630,000 shares) [3]